thiophenes has been researched along with s 3304 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kambayashi, Y; Sollie, F; van Marle, S; van Vliet, A; Yamada-Sawada, T | 1 |
| Amin, DM; Bradford, D; Kambayashi, Y; Mant, TG; Pisupati, J; Tanaka, K; Yamada-Sawada, T; Yano, Y | 1 |
| Bukowski, R; Chiappori, AA; Creaven, PJ; Eckhardt, SG; Ikeda, M; Javle, MM; Kambayashi, Y; Mekhail, T; O'bryant, CL; Sullivan, DM; Tanaka, K; Yamada-Sawada, T; Yano, Y | 1 |
3 trial(s) available for thiophenes and s 3304
| Article | Year |
|---|---|
Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
Topics: Adolescent; Adult; Alanine Transaminase; Area Under Curve; Cross-Over Studies; Double-Blind Method; Glutamyl Aminopeptidase; Humans; Hydrocortisone; Indoles; Male; Thiophenes; Tissue Inhibitor of Metalloproteinases | 2005 |
Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Indoles; Male; Matrix Metalloproteinase Inhibitors; Thiophenes | 2007 |
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Indoles; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thiophenes | 2007 |